Small molecule immunometabolic modulator

Class

Small molecule immunometabolic modulator (NAD+ metabolism modulator that drives macrophage repolarization from M1-like inflammatory to M2-like anti-inflammatory phenotype, suppressing iNOS and increasing Arg-1, alongside a shift from anabolic to catabolic cellular metabolism; no single discrete protein target confirmed in public literature)

Pathway

NAD+ modulation of intestinal macrophages / macrophage polarization (M1→M2) immunometabolism

Notes

original target text: Small molecule immunometabolic modulator (NAD+ metabolism modulator that drives macrophage repolarization from M1-like inflammatory to M2-like anti-inflammatory phenotype, suppressing iNOS and increasing Arg-1, alongside a shift from anabolic to catabolic cellular metabolism; no single discrete protein target confirmed in public literature)

Macrophages are innate immune cells that adopt different functional states depending on tissue context and signals. In inflamed tissue, macrophages often skew toward an "M1-like" pro-inflammatory phenotype, producing inducible nitric oxide synthase (iNOS) and reactive mediators that damage tissue and perpetuate immune activation. An alternative "M2-like" phenotype, marked by arginase-1 (Arg-1) expression, is associated with tissue repair and resolution of inflammation. This mechanism describes a small molecule that shifts macrophage metabolism to favor the M2-like state over the M1-like state, rather than acting through a single, well-defined receptor or enzyme. It does so by modulating nicotinamide adenine dinucleotide (NAD+), a coenzyme central to cellular energy metabolism and to enzymes that sense the metabolic state of a cell. By changing NAD+ availability, the compound is thought to push macrophages from an anabolic, glycolysis-driven program that supports inflammatory output toward a more catabolic, oxidative program associated with anti-inflammatory function. This immunometabolic approach is relevant to chronic inflammatory conditions where macrophages sustain tissue damage, with intestinal inflammation, such as inflammatory bowel disease, being a principal context in which rebalancing local macrophage populations toward a reparative phenotype could reduce ongoing tissue injury.